News & Updates


Aripiprazole (Abilify, Abilify Maintena, Aristada) - Further FDA Warnings About New Impulse-Control Problems

2017-04-25 10:24:01 | Category : Medical Device & Drugs
On May 3, 2016 the U.S. Food and Drug Administration (FDA) added warnings about compulsive behaviors associated with aripiprazole products including Abilify, Abilify Maintena, Aristada. Pathological gambling is already listed as a reported effect. The current warning, however, doesn’t comprehensively cover the impulse-control risk identified by the FDA. FDA reported other compulsive behaviors such as compulsive eating, shopping and sexual actions are associated with aripiprazole. Read the entire FDA Aripiprazole (Abilify, Abilify Maintena, Aristada) release here. Read Related Articles: Abilify Linked to Compulsive Gambling

Archived News & Updates

Honors and Awards